Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: cilomilast

Study type: Interventional

Funder types: Industry

Identifiers

NCT00103922

CIL103657

Details and patient eligibility

About

This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)

Enrollment: 600 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of COPD and a history of cigarette smoking.

Exclusion criteria

• Significant heart or lung disease not associated with COPD.
• Significant stomach or intestinal disease.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

600 participants in 1 patient group

Arm 1

Experimental group

Treatment:

Drug: cilomilast